Efficacy and safety of 2mg/day of M100907 [volinanserin] on sleep maintenance insomnia with a sub-study of the effect of M100907 on stable type II diabetes mellitus: a one year, multi-center, randomized, double-blind, placebo-controlled study.
Phase of Trial: Phase III
Latest Information Update: 28 May 2016
At a glance
- Drugs Volinanserin (Primary)
- Indications Sleep maintenance insomnia
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms SAMS
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 04 Mar 2016 Last checked against European Clinical Trials Database record.
- 01 Sep 2009 Actual patient number (1847) added as reported by ClinicalTrials.gov.